Key result
cMyBP-C phosphorylation decreases myosin and actin binding while HCM-linked mutations increase it.
Why the study?
cMyBP-C phosphorylation is significantly altered in cardiomyopathies and heart failure, but how cMyBP-C interacts with myosin and actin required investigation.
Answers are grounded in this paper and cite their sources.
Phosphorylation and HCM-linked mutations have opposite effects on the binding of cMyBP-C to myosin and actin, highlighting the critical role of cMyBP-C phosphorylation in normal cardiac function and the potential for targeted therapies.
N-terminal cardiac myosin-binding protein C (cMyBP-C) domains (C0-C2) bind to thick (myosin) and thin (actin) filaments to coordinate contraction and relaxation of the heart. These interactions are regulated by phosphorylation of the M-domain situated between domains C1 and C2. In cardiomyopathies and heart failure, phosphorylation of cMyBP-C is significantly altered. We aimed to investigate how cMyBP-C interacts with myosin and actin. We developed complementary, high-throughput, C0-C2 FRET-based binding assays for myosin and actin to characterize the effects due to 5 HCM-linked variants or functional mutations in unphosphorylated and phosphorylated C0-C2. The assays indicated that phosphorylation decreases binding to both myosin and actin, whereas the HCM mutations in M-domain generally increase binding. The effects of mutations were greatest in phosphorylated C0-C2, and some mutations had a larger effect on actin than myosin binding. Phosphorylation also altered the spatial relationship of the probes on C0-C2 and actin. The magnitude of these structural changes was dependent on C0-C2 probe location (C0, C1, or M-domain). We conclude that binding can differ between myosin and actin due to phosphorylation or mutations. Additionally, these variables can change the mode of binding, affecting which of the interactions in cMyBP-C N-terminal domains with myosin or actin take place. The opposite effects of phosphorylation and M-domain mutations is consistent with the idea that cMyBP-C phosphorylation is critical for normal cardiac function. The precision of these assays is indicative of their usefulness in high-throughput screening of drug libraries for targeting cMyBP-C as therapy.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2023) studied Cardiomyopathies and heart failure. Phosphorylation and HCM-linked M-domain mutations in cMyBP-C vs. Unphosphorylated and wild-type cMyBP-C was evaluated on Binding to myosin and actin. Phosphorylation of cMyBP-C decreases binding to myosin and actin, whereas HCM-linked M-domain mutations generally increase binding, with the greatest effects seen in the phosphorylated state.
Synapse has enriched 10 related papers. Consider them for comparative context: